JP6136032B2 - 新規な２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン、Ｇタンパク質共役受容体ＧＰＲ１１９のモジュレーターとしてのそれらの使用、及びそれらを含む医薬組成物 - Google Patents
新規な２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン、Ｇタンパク質共役受容体ＧＰＲ１１９のモジュレーターとしてのそれらの使用、及びそれらを含む医薬組成物 Download PDFInfo
- Publication number
- JP6136032B2 JP6136032B2 JP2015510758A JP2015510758A JP6136032B2 JP 6136032 B2 JP6136032 B2 JP 6136032B2 JP 2015510758 A JP2015510758 A JP 2015510758A JP 2015510758 A JP2015510758 A JP 2015510758A JP 6136032 B2 JP6136032 B2 JP 6136032B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- cycloalkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1ncn[o]1 Chemical compound *c1ncn[o]1 0.000 description 10
- NARRCMFIGZJIMK-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(C2)(CC2(C2)Oc3c2cc(-c(cc2)ccc2S(C)(=O)=O)nc3)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(C2)(CC2(C2)Oc3c2cc(-c(cc2)ccc2S(C)(=O)=O)nc3)CC1)=O NARRCMFIGZJIMK-UHFFFAOYSA-N 0.000 description 1
- NWMXUNXYQANMQE-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(C2)(CC2(C2)Oc3c2cc(-c(ccc(N)c2)c2F)nc3)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(C2)(CC2(C2)Oc3c2cc(-c(ccc(N)c2)c2F)nc3)CC1)=O NWMXUNXYQANMQE-UHFFFAOYSA-N 0.000 description 1
- VZFKFGSLSPTUHS-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(C2)(CC2(Cc2c3)Oc2cnc3N(CC2)CCN2S(C)(=O)=O)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(C2)(CC2(Cc2c3)Oc2cnc3N(CC2)CCN2S(C)(=O)=O)CC1)=O VZFKFGSLSPTUHS-UHFFFAOYSA-N 0.000 description 1
- WOJMPGXTXWZUKF-UHFFFAOYSA-N CC(C)(CN1CCC(C2)(CC2(Cc2c3)Oc2cnc3-c(cc2)ccc2S(C)(=O)=O)CC1)O Chemical compound CC(C)(CN1CCC(C2)(CC2(Cc2c3)Oc2cnc3-c(cc2)ccc2S(C)(=O)=O)CC1)O WOJMPGXTXWZUKF-UHFFFAOYSA-N 0.000 description 1
- PPGAKRWCABNOMO-UHFFFAOYSA-N CC1(CC1)OC(N1CCC(C2)(CC2(C2)Oc3c2cc(C(CC2)=CCN2S(C)(=O)=O)nc3)CC1)=O Chemical compound CC1(CC1)OC(N1CCC(C2)(CC2(C2)Oc3c2cc(C(CC2)=CCN2S(C)(=O)=O)nc3)CC1)=O PPGAKRWCABNOMO-UHFFFAOYSA-N 0.000 description 1
- IXPVNCKAYKZBQY-UHFFFAOYSA-N CC1=NOCN1 Chemical compound CC1=NOCN1 IXPVNCKAYKZBQY-UHFFFAOYSA-N 0.000 description 1
- BKUQVCVAPOWJLW-UHFFFAOYSA-N CCC1(CC1)C(F)(F)F Chemical compound CCC1(CC1)C(F)(F)F BKUQVCVAPOWJLW-UHFFFAOYSA-N 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N CCc1ncccc1 Chemical compound CCc1ncccc1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- RILVNLMOTMFTMQ-UHFFFAOYSA-N CCc1ncccn1 Chemical compound CCc1ncccn1 RILVNLMOTMFTMQ-UHFFFAOYSA-N 0.000 description 1
- LRRAWVCWXFNZIO-UHFFFAOYSA-N CS(N(CC1)CC=C1c(nc1)cc2c1OC(C1)(CC1(CC1)CCN1c1nnc(C(F)(F)F)[s]1)C2)(=O)=O Chemical compound CS(N(CC1)CC=C1c(nc1)cc2c1OC(C1)(CC1(CC1)CCN1c1nnc(C(F)(F)F)[s]1)C2)(=O)=O LRRAWVCWXFNZIO-UHFFFAOYSA-N 0.000 description 1
- MRDKBTPJKPSZCS-INIZCTEOSA-N C[C@@H](C(F)(F)F)OC(N1CCC(C2)(CC2(C2)Oc3c2cc(C(CC2)=CCN2S(C)(=O)=O)nc3)CC1)=O Chemical compound C[C@@H](C(F)(F)F)OC(N1CCC(C2)(CC2(C2)Oc3c2cc(C(CC2)=CCN2S(C)(=O)=O)nc3)CC1)=O MRDKBTPJKPSZCS-INIZCTEOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12166992.3 | 2012-05-07 | ||
| EP12166992 | 2012-05-07 | ||
| PCT/EP2013/059346 WO2013167514A1 (en) | 2012-05-07 | 2013-05-06 | New 2,3-dihydro-furo[2,3-c]pyridines, their use as modulators of the g-protein-coupled receptor gpr119 and pharmaceutical compositions comprising them |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516001A JP2015516001A (ja) | 2015-06-04 |
| JP2015516001A5 JP2015516001A5 (enExample) | 2016-06-23 |
| JP6136032B2 true JP6136032B2 (ja) | 2017-05-31 |
Family
ID=48325708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510758A Active JP6136032B2 (ja) | 2012-05-07 | 2013-05-06 | 新規な２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン、Ｇタンパク質共役受容体ＧＰＲ１１９のモジュレーターとしてのそれらの使用、及びそれらを含む医薬組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8809361B2 (enExample) |
| EP (1) | EP2847196B1 (enExample) |
| JP (1) | JP6136032B2 (enExample) |
| WO (1) | WO2013167514A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021236654A1 (en) * | 2020-05-18 | 2021-11-25 | The Johns Hopkins University | Anti-cancer spirocyclic-guanidine compounds and uses thereof |
| EP4153589A4 (en) | 2020-05-19 | 2024-06-12 | Kallyope, Inc. | AMPK ACTIVATORS |
| WO2021263039A1 (en) | 2020-06-26 | 2021-12-30 | Kallyope, Inc. | Ampk activators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140161A1 (en) * | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| WO2012077655A1 (ja) * | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体 |
| UY33805A (es) * | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| EA201300846A1 (ru) * | 2011-01-21 | 2013-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Конденсированные дигидрофураны в качестве модуляторов gpr119, предназначенные для лечения диабета, ожирения и родственных нарушений |
-
2013
- 2013-05-06 US US13/887,887 patent/US8809361B2/en active Active
- 2013-05-06 EP EP13720937.5A patent/EP2847196B1/en active Active
- 2013-05-06 WO PCT/EP2013/059346 patent/WO2013167514A1/en not_active Ceased
- 2013-05-06 JP JP2015510758A patent/JP6136032B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2847196A1 (en) | 2015-03-18 |
| JP2015516001A (ja) | 2015-06-04 |
| EP2847196B1 (en) | 2017-10-25 |
| WO2013167514A1 (en) | 2013-11-14 |
| US8809361B2 (en) | 2014-08-19 |
| US20130296354A1 (en) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6011543B2 (ja) | 糖尿病、肥満および関連疾患の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン | |
| JP5703393B2 (ja) | 糖尿病、肥満および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン | |
| JP5935154B2 (ja) | Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド | |
| JP7049349B2 (ja) | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7049353B2 (ja) | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 | |
| JP7023969B2 (ja) | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| CN110088089B (zh) | 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途 | |
| JP6094578B2 (ja) | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン | |
| JP2020505402A (ja) | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP6066126B2 (ja) | 新規化合物、医薬組成物及びその使用 | |
| JP6136032B2 (ja) | 新規な２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン、Ｇタンパク質共役受容体ＧＰＲ１１９のモジュレーターとしてのそれらの使用、及びそれらを含む医薬組成物 | |
| JP6263789B2 (ja) | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 | |
| JP6119081B2 (ja) | Ｇｐｒ１１９に対するフロ［２，３−ｃ］ピリジン活性物質 | |
| JP6212827B2 (ja) | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド誘導体、およびｇｐｒ１１９モジュレーターとしてのそれらの使用 | |
| JP6119088B2 (ja) | ２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン−２−イル−ピペリジン誘導体、それらを含む医薬組成物及びその使用 | |
| JP2015523404A (ja) | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 | |
| TW201305144A (zh) | 新穎化合物、醫藥組合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160506 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160506 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170314 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170405 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170413 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6136032 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |